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Abstract 18 
Pharmaceutical removal could be significantly enhanced through cometabolism during 19 
nitrification processes. So far pharmaceutical biotransformation models have not considered 20 
the formation of transformation products associated with the metabolic type of 21 
microorganisms. Here we reported a comprehensive model to describe and evaluate the 22 
biodegradation of pharmaceuticals and the formation of their biotransformation products by 23 
enriched nitrifying cultures. The biotransformation of parent compounds was linked to the 24 
microbial processes via cometabolism induced by ammonium oxidizing bacteria (AOB) 25 
growth, metabolism by AOB, cometabolism by heterotrophs (HET) growth and metabolism 26 
by HET in the model framework. The model was calibrated and validated using experimental 27 
data from pharmaceuticals biodegradation experiments at realistic levels, taking two 28 
pharmaceuticals as examples, i.e., atenolol and acyclovir. Results demonstrated the good 29 
prediction performance of the established biotransformation model under different metabolic 30 
conditions, as well as the reliability of the established model in predicting different 31 
pharmaceuticals biotransformations. The linear positive correlation between ammonia 32 
oxidation rate and pharmaceutical degradation rate confirmed the major role of cometabolism 33 
induced by AOB in the pharmaceutical removal. Dissolved oxygen was also revealed to be 34 
capable of regulating the pharmaceutical biotransformation cometabolically and the substrate 35 
competition between ammonium and pharmaceuticals existed especially at high ammonium 36 
concentrations. 37 
 38 
Keywords: Cometabolism, pharmaceutical, model, ammonia oxidizing bacteria, 39 
biotransformation product, substrate competition 40 
  41 
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Introduction 42 
The ubiquitous occurrence and fate of pharmaceuticals in the environment and 43 
engineering systems have attracted the concerns of the scientists and the public for decades 44 
due to their potential ecotoxic impact on aquatic ecosystems.1,2 These organic compounds 45 
were present in the wastewater at concentrations ranging from pg L-1 to µg L-1.3,4 As the 46 
wastewater treatment plants (WWTPs) were originally designed for chemical oxygen demand 47 
and other nutrients removal, the incomplete removal was found for pharmaceuticals in the 48 
treatment processes, being a major pathway for pharmaceuticals to enter the environment.5  49 
Autotrophic biomass (e.g., enriched nitrifying sludge) was capable of transforming the 50 
pharmaceuticals cometabolically during the wastewater treatment process and thus the 51 
pharmaceutical removal was reported to be positively correlated to nitrification rate.6,7 52 
Ammonia oxidizing bacteria (AOB) in the nitrifying biomass could degrade a broad range of 53 
substrates including aromatic and aliphatic compounds due to the non-specific enzyme 54 
ammonia monooxygenase (AMO).8-10 The presence of the growth substrate (i.e. ammonium) 55 
was required for cometabolism which should be taken into account when predicting the fate 56 
of pharmaceuticals.11 In addition to cometabolism, pharmaceuticals could also be degraded as 57 
the energy and carbon source for microorganisms through metabolic biotransformation.11 58 
Furthermore, the formed biotransformation products might be more toxic and persistent.12 59 
Hence the biotransformation products should be considered for a more comprehensive 60 
understanding of the fate of pharmaceuticals in the nitrifying activated sludge. 61 
Mathematical modeling offers a useful tool and is adopted widely to analyze complicated 62 
metabolic pathways. Cometabolic biotransformations were previously modeled through first-63 
order kinetics and mixed order kinetics like Monod expression13-15 and have evolved from 64 
only considering the cometabolic substrates to incorporating the relationships between 65 
cometabolic substrates and growth substrates, such as competitive interaction and toxicity 66 
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inhibition.15 However, the previous literature has rarely considered the formation of 67 
biotransformation products in the cometabolic biotransformation models for pharmaceuticals.  68 
The aim of this work is to develop and test a comprehensive modeling framework to 69 
describe the pharmaceuticals biotransformation at realistic levels as well as the formation of 70 
their biotransformation products by the enriched nitrifying sludge under different metabolic 71 
conditions. Microbial processes contributing to the pharmaceutical biotransformation were 72 
considered as follows: growth-linked cometabolism by AOB, metabolic transformation by 73 
AOB, growth-linked cometabolism by heterotrophs (HET) and metabolic transformation by 74 
HET. To this end, atenolol and acyclovir were selected as the model compounds in this study 75 
as they were frequently found in the wastewater with the highest concentrations of 25 and 1.8 76 
µg L-1, respectively, which have been reported to be increasingly removed under nitrifying 77 
conditions.16-18 It has been reported that they can be biotransformed into atenolol acid and 78 
carboxy-acyclovir, respectively.18,19 Model calibration and validation were carried out with 79 
experimental data using atenolol as parent compounds under different metabolic conditions. 80 
Model evaluation was also conducted using the experimental data from acyclovir 81 
biotransformation. The effects of dissolved oxygen (DO) and ammonium concentrations on 82 
pharmaceutical biotransformation were investigated using the validated model to provide 83 
insights into the process dynamics. The reported model in this work is expected to be used as 84 
a tool to fully understand the fate of pharmaceuticals associated with different metabolisms 85 
by responsible microorganisms in the complicated activated sludge system. 86 
 87 
Materials and Methods 88 
 89 
Model development 90 
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A multi-species and multi-substrate model was developed to describe the pharmaceutical 91 
biotransformation processes by the enriched nitrifying sludge. This biotransformation model 92 
comprehensively considered the consumption of the pharmaceuticals and the formation of 93 
transformation products accompanied with the simultaneous nitrification in the enriched 94 
nitrifying sludge. It describes the relationships among eight soluble substrates as defined in 95 
Table S1 in Supporting Information (SI), i.e., ammonium (SNH4), nitrite (SNO2), nitrate (SNO3), 96 
readily biodegradable substrates (SS), oxygen (SO2), pharmaceutical (parent compound, PC, 97 
SPC), primary biotransformation product (BP, SBP) and other biotransformation products (OP, 98 
SOP), and five particulate species, i.e., AOB (XAOB), HET (XHET), NOB (nitrite oxidizing 99 
bacteria, XNOB), slowly biodegradable substrates (XS) and inert biomass (XI). Nine processes 100 
are considered: (1) metabolic transformation of PC by AOB; (2) cometabolic transformation 101 
of PC coupled to growth of AOB; (3) endogenous decay of AOB; (4) hydrolysis; (5) 102 
metabolic transformation of PC by HET; (6) cometabolic transformation of PC coupled to 103 
growth of HET; (7) endogenous decay of HET; (8) growth of NOB; and (9) endogenous 104 
decay of NOB. The kinetic expressions and the stoichiometric matrix of the proposed 105 
biotransformation model are summarized in Tables S2 and S3 in SI, respectively. The 106 
definitions, values, units and sources of all parameters used in the biotransformation model 107 
are listed in Table S4 in SI.  108 
Pharmaceutical biodegradation was reported to be linked to AOB due to the non-specific 109 
enzyme AMO as well as HET, which was not related to the activity of NOB.20 In this model, 110 
the microbial growth-linked kinetic expressions (processes 2 and 6 in Table S2 in SI) are 111 
described using the Monod equations, which are associated with cometabolic 112 
biotransformation of pharmaceuticals.20 The concentration of growth substrates SNH4 and SS 113 
is also involved in the Monod equations. The basis of the cometabolic biotransformation 114 
expressions is the concept of transformation coefficient parameters such as AOB growth-115 
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linked T
PC-AOB
c  and HET growth-linked T
PC-HET
c . The pharmaceutical biotransformation 116 
reactions directly conducted via metabolism by AOB and HET are described by pseudo-first 117 
order kinetic expressions (processes 1 and 5 in Table S2 in SI). For each reaction, the rate is 118 
expressed by an explicit function of the concentrations of relevant pharmaceuticals in the 119 
process. For microbial metabolic biodegradation of PC, the key parameters are biomass 120 
normalized PC degradation rate coefficients in the absence of AOB and HET growth, i.e. 121 
kPC-AOB  and kPC-HET . Processes 1, 2, 5 and 6 together contribute to pharmaceutical 122 
biotransformation in the enriched nitrifying sludge. 123 
The formation of biotransformation products is modeled using the specific stoichiometry 124 
coefficients in processes 1, 2, 5 and 6. The coefficients αBP
m  and αBP
c  indicate the 125 
transformation of PC to BP under metabolism and cometabolism conditions by AOB, 126 
respectively. Similarly, the coefficients β
BP
m  and β
BP
c  present the transformation of PC to BP 127 
under metabolism and cometabolism conditions by HET, respectively.  128 
 129 
Atenolol and acyclovir biotransformation experiments 130 
Experimental data from our previous biodegradation experiments of atenolol (Case I) 131 
and acyclovir (Case II) under different conditions by an enriched nitrifying sludge were used 132 
for model evaluation in this work.21,22 The chemicals used in the batch experiments and the 133 
enrichment of nitrifying cultures in the sequencing batch reactor (SBR) are described in Text 134 
S1 and S2 in SI. Details of the experimental conditions applied in different scenarios are 135 
provided in Table S5 in SI. Briefly, 4-L beaker was used as the batch reactor with enriched 136 
nitrifying cultures inoculated to degrade parent compounds at an initial 15 µg L-1. The mixed 137 
liquid suspended solid (MLVSS) concentration was kept at approximately 1 g L-1. All the 138 
batch experiments were conducted in duplicates. The designs for Experiments 1-3 were same 139 
for atenolol (Case I) and acyclovir (Case II). In Experiment 1, 30 mg L-1 allylthiourea (ATU) 140 
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was added to inhibit nitrifying activities,20,23,24 leading to the dominant contribution from 141 
HET to pharmaceutical biotransformation.11 Initial ammonium concentration was provided at 142 
50 mg-N L-1. No external ammonium was supplied during the entire experimental period 143 
(240 h). In Experiment 2, no initial and external ammonium was provided during 240 h. In 144 
Experiment 3, constant ammonium concentration was maintained at 50 mg-N L-1 by dosing a 145 
mixture of ammonium bicarbonate and potassium bicarbonate as ammonium feeding solution 146 
and pH buffer at the same time, which could ensure the cometabolic biotransformation by 147 
AOB. The Experiment 4 was exclusively designed for atenolol biotransformation, where 148 
constant ammonium concentrations of 25 mg-N L-1 were provided using the dosing method 149 
in Experiment 3 during the experimental period. Samples were collected periodically to 150 
analyse mixed liquid suspended solid (MLSS) concentration and its volatile fraction (i.e., 151 
MLVSS), NH4
+, NO2
-, NO3
-, atenolol, acyclovir and their biotransformation products 152 
atenolol acid and carboxy-acyclovir. The detailed chemical analysis procedures could be 153 
found in the previous work.21,22,25  154 
The contribution of sorption to removal of atenolol and acyclovir was insignificant based 155 
on our previous studies.22,25 This is in consistent with low sorption coefficient KD (0.04) of 156 
atenolol and low octanol-water partition coefficient Log KOW (0.16) of atenolol as well as Log 157 
KOW (-1.59) of acyclovir.
26-28 Volatilization was considered negligible given the low values of 158 
Henry’s law constants for atenolol (1.37×10-18 atm m3 mol-1) and acyclovir (3.2×10-22 atm m3 159 
mol-1).29 Hydrolysis would not contribute to the degradation of atenolol and acyclovir, which 160 
was confirmed previously and was in consistent with the absence of their transformation 161 
products.22,25 Photodegradation was also insignificant considering the turbidity of the sludge 162 
and the aluminum foil covering the reactor. Therefore, microbially induced biodegradation 163 
should be the main mechanism for pharmaceutical removal in both atenolol and acyclovir 164 
biotransformation experiments. 165 
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 166 
Model calibration and validation 167 
The biotransformation model used in this work consists of 9 biochemical processes and 168 
27 stoichiometric and kinetic parameters (as shown in Tables S2 and S4 in SI). Most of these 169 
parameters were well established in previous literature, therefore the reported values were 170 
directly used in this developed model. However, the information on biomass growth-linked 171 
PC transformation coefficients T
PC-AOB
c  and T
PC-HET
c  and microbial endogenous 172 
transformation coefficients kPC-AOB  and kPC-HET  was limited.
20 Considering the key role of 173 
cometabolism induced by AOB growth in biotransformation, the maximum specific growth 174 
rate of AOB µ
max, AOB
 was of significance to the developed model. Furthermore, the 175 
sensitivity analysis suggested the four key parameters kPC-AOB, kPC-HET, TPC-AOB
c and µ
max, AOB
 176 
are highly sensitive to the biotransformation processes in terms of the experimental 177 
measurements (examples shown in Figure S1 in SI). Model calibration was therefore 178 
conducted to estimate the values of kPC-AOB , kPC-HET , TPC-AOB
c and µ
max, AOB
 based on 179 
experimental measurements through minimizing the sum of squares of the deviations 180 
between the measured and modeled values for the concentrations of parent compounds and 181 
biotransformation products under different conditions. In addition, the four stoichiometric 182 
coefficients, i.e., αBP
m , αBP
c , β
BP
m  and β
BP
c , for the transformation of PC to BP under metabolism 183 
and cometabolism conditions could be determined based on the respective molecular mass 184 
and concentrations of BP and PC measured in the experiments.  185 
Experimental data from atenolol biotransformation (Case I) of Experiments 1-3 were 186 
firstly used for model calibration. Concentrations of ammonium, nitrite, DO, atenolol and 187 
atenolol acid from Experiment 1 and Experiment 2 were fitted by model simulations to 188 
estimate kPC-HET andkPC-AOB, respectively, whereas concentrations of ammonium, nitrite, DO, 189 
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atenolol and atenolol acid from Experiment 3 were fitted to estimate µ
max, AOB
 and T
PC-AOB
c , 190 
using the kPC-HET and kPC-AOB  values obtained in previous experiments (Experiment 1 and 191 
Experiment 2). Model validation was then carried out with the calibrated parameters using 192 
the independent experimental data sets from atenolol biotransformation of Experiment 4.21 193 
Specifically, in Experiment 4, batch experiments with atenolol as the parent compound at an 194 
initial concentration of 15 µg L-1 were conducted using the same enriched nitrifying sludge 195 
(i.e., same microbial composition) in the constant presence of ammonium of 25 mg-N L-1 and 196 
at DO of around 2.5 mg L-1. There were no significant gaps between batch experiments, 197 
leading to insignificant biomass changes. The ammonium and DO concentrations applied 198 
were different from of Experiment 3 at ammonium of 50 mg-N L-1 and DO of 3.0 mg L-1 199 
(Table S5 in SI). To further verify the validity and applicability of the model, the model was 200 
also applied to evaluating the acyclovir biotransformation data from Case II of Experiments 201 
1-3. The key model parameters were recalibrated for Case II using the three sets of batch 202 
experimental data (Table S5 in SI).  203 
The sensitivity analysis, parameter estimation, parameter uncertainty evaluation and 204 
model simulations were done through employing a modified version of software AQUASIM 205 
2.1d according to Batstone et al.30, with a 95% confidence level for significance testing and 206 
parameter uncertainty analysis. The standard errors and 95% confidence intervals of 207 
individual parameter estimates were calculated from the mean square fitting errors and the 208 
sensitivity of the model to the parameters. Residual sum of squares (RSS) between the 209 
objective data and model was used as the objective function. 210 
 211 
Results 212 
 213 
Model calibration with experimental data from atenolol biotransformation 214 
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As atenolol acid was the sole biotransformation products with no other products 215 
identified in all batch experiments, the dynamics of the substrate  was not modeled herein. 216 
The model was first calibrated to illustrate the biotransformation of atenolol catalysed solely 217 
by HET in Experiment 1 (i.e. with addition of ATU to inhibit the nitrifying activity). Given 218 
that no exogenous organic carbon was supplied during culture enrichment and the only 219 
organic carbon in the batch experiments was pharmaceuticals, the growth of HET was 220 
considered extremely low and the cometabolic transformation rate of pharmaecuticals linked 221 
to growth of HET was not modeled with T
PC-HET
c  omitted for estimation.20 With AOB related 222 
parameters kPC-AOB and TPC-AOB
c  set to zero, only the parameter 	 was estimated with 223 
its best-fit value shown in Table 1 for Experiment 1. The predicted atenolol and atenolol acid 224 
concentration profiles with the established model were demonstrated in Figure 1A, along 225 
with the measured experimental values. Atenolol experienced a continuous decrease by 94.3% 226 
from the beginning to the end of experiments accompanied with a gradual increase of 227 
atenolol acid until 168 h and a stable stage until 240 h at a conversion efficiency of 62.6% 228 
(Figure 1A), which was well captured by the model predictions. 229 
The experimental data obtained from Experiment 2 (i.e., in the absence of ammonium) 230 
were used to further calibrate the developed model in terms of atenolol and atenolol acid 231 
dynamics. Without the presence of the growth substrate, the ammonium released from cell 232 
lysis process during bacterial decay was minor and AOB growth-linked cometabolism would 233 
be considered to have negligible contribution to atenolol biotransformation. Therefore, only 234 
the metabolic biotransformation by AOB and HET were involved in the biotransformation of 235 
atenolol for Experiment 2. The parameter value of kPC-HET obtained in Experiment 1 was 236 
used directly without any modification. Another key model parameter kPC-AOB related to AOB 237 
metabolism was thus reliably estimated during atenolol biotransformation (value as shown in 238 
Table 1). As shown in Figure 1B, although atenolol demonstrated a sharp decrease by 97.4% 239 
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over the whole experimental period, the production of atenolol acid indicated a lower 240 
transformation efficiency in the absence of ammonium (29.1%) compared with the 241 
experiments with addition of ATU (see Figure 1A), again well matching the model 242 
predictions.   243 
In Experiment 3, the presence of ammonium at 50 mg-N L-1 was provided constantly to 244 
ensure the cometabolic biodegradation of atenolol by both AOB and HET at DO of 3.0 mg L-245 
1. Together with the rest of the parameters involved, the parameter values of kPC-HET and 246 
kPC-AOB  estimated in the previous two experiments were applied in the biotransformation 247 
model. The key parameters related to AOB induced cometabolism, i.e., T
PC-AOB
c  and µ
max, AOB
, 248 
were then estimated with the optimum values listed in Table 1. Figure S2A in SI showed the 249 
well agreement between predicted and measured concentrations of ammonium, nitrite and 250 
DO based on the proposed model, supporting the capability of the model to describe the two-251 
step nitrification processes in terms of nitrite accumulation, as well as the suitability of the 252 
selected parameters related to DO dynamics for the cometabolic biodegradation processes by 253 
the enriched nitrifying culture (i.e., the KO2,AOB and KO2,HET values for AOB and HET). It 254 
should be noted that the nitrate concentrations were not specifically modeled, which were 255 
slightly higher than that in the SBR in all experiments since the biomass in batch experiments 256 
was taken directly from SBR with a background nitrate concentration up to 1000 mg L-1. As 257 
shown in Figure 1C, concomitant with the gradual decrease of atenolol at a removal 258 
efficiency of 88.0%, atenolol acid was formed at an increasing trend with 86.9% conversion 259 
efficiency. This was obviously higher than the experiments in the absence of ammonium and 260 
with the addition of ATU, indicating a positive role of AOB induced cometabolism in 261 
atenolol transformation. The model described these observations reasonably well. 262 
Overall, the developed model could satisfactorily capture all dynamics associated with 263 
atenolol and atenolol acid in all batch biodegradation experiments under different metabolic 264 
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conditions. The good agreement between model simulations and measured data in Figure 1 265 
supports the capability of the developed model in describing the microbial growth related 266 
biotransformation of atenolol in enriched nitrifying cultures. The obtained parameter linked 267 
to AOB growth during ammonia oxidation, i.e., AOB-induced cometabolic atenolol 268 
transformation coefficient T
PC-AOB
c , was estimated at 0.012 ± 0.000036 m3 g COD-1. It was 269 
lower than the reported value of 0.0715 ± 0.0227 m3 g COD-1 for atenolol biodegradation by 270 
an enriched nitrifying sludge.20 The non-growth metabolism by HET and the non-growth 271 
metabolism by AOB on atenolol biodegradation also described the experimental data with the 272 
addition of ATU and in the absence of ammonium well. The estimated parameters of kPC-HET 273 
and kPC-AOB were 0.000180 ± 0.000017 and 0.000140 ± 0.000012 m
3 g COD-1 h-1, which were 274 
lower than but in the same order of magnitude as the literature reported values (0.00093 ± 275 
0.00018 and 0.00067 ± 0.00023 m3 g COD-1 h-1, respectively).20 The discrepancy in these 276 
parameters values could be probably ascribed to the difference in the community structure in 277 
the adopted nitrifying cultures or different operating conditions. The model could be 278 
potentially applied to a widespread extent despite that the parameter values would vary 279 
according to the experimental conditions. As suggested, it was difficult to compare these 280 
coefficients (kPC-HET , kPC-AOB  and TPC-AOB
c ) with other pharmaceuticals as most existing 281 
models did not consider the specific biochemical processes.20 282 
 283 
Model validation with atenolol biotransformation under different conditions 284 
In order to further confirm the validity and reliability of the developed model, model 285 
validation was carried out to compare the model simulations to the independent experimental 286 
data, which were not used for model calibration. Based on the measured concentrations of 287 
atenolol and atenolol acid, the stoichiometric coefficients αBP
c  and αBP
m  were calculated as 0.58 288 
and 0.58, respectively. Applied with previously calibrated parameters in Table 1, the 289 
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proposed biotransformation model was used to predict dynamics of ammonium, nitrite, DO, 290 
atenolol and atenolol acid in the presence of ammonium at a constant concentration of 25 mg-291 
N L-1 and at DO of around 2.5 mg L-1 (significantly different from the ammonium of 50 mg-292 
N L-1 and DO of 3.0 mg L-1 used for model calibration). The model captured the dynamics of 293 
ammonium, nitrite and DO, again suggesting the validity of the two-step nitrification model 294 
and the suitability of the selected parameters related to DO (see Figure S2B). As shown in 295 
Figure 2, atenolol continuously dropped from initial 15 µg L-1 with a final degradation 296 
efficiency of 92.9%. The conversion rate of atenolol acid transformed from atenolol was 297 
calculated as 57.9%. The model predictions could capture these trends of atenolol 298 
degradation and atenolol acid formation very well, which again supports the validity of the 299 
developed model for atenolol biotransformation.  300 
 301 
Model evaluation with experimental data from acyclovir biotransformation 302 
The experimental results obtained with Case II for biotransformation of acyclovir were 303 
used to further evaluate the developed model. The developed biotransformation model was 304 
recalibrated for acyclovir biodegradation and carboxy-acyclovir formation dynamics under 305 
different conditions. Most of the literature reported model parameters were employed at same 306 
values as the case of atenolol except the stoichiometry coefficients (αBP
m , αBP
c , β
BP
m , β
BP
c ) for 307 
formation of carboxy-acyclovir associated with specific biochemical processes (as shown in 308 
Table S4 in SI), which were calculated based on the experimental data. The values for the 309 
three key parameters kPC-HET, kPC-AOB and TPC-AOB
c  were recalibrated, which were associated 310 
with the investigated parent compound. As the enriched nitrifying biomass utilized in the 311 
batch biodegradation experiments of acyclovir were same as those in case of atenolol, the 312 
maximum growth rate of AOB µ
max, AOB
 was set to be the same as in case of atenolol during 313 
model calibration for acyclovir biotransformation in the presence of ammonium. The 314 
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obtained parameter values for acyclovir biotransformation were 0.00035 ± 0.00002 m3 g 315 
COD-1 h-1 (kPC-HET), 0.00005 ± 0.00003 m
3 g COD-1 h-1 (kPC-AOB) and 0.00093 ± 0.00049 m
3 g 316 
COD-1 (T
PC-AOB
c ). 317 
The model predictions of acyclovir biotransformation matched the experimental results 318 
well under different conditions (Figure 3), further demonstrating the validity of the 319 
established model. Parameters values giving the optimum fits with the experimental data 320 
were difficult to compare reliably with literature values as this study firstly reported the AOB 321 
cometabolic acyclovir transform coefficient T
PC-AOB
c . However, compared to other reported 322 
compounds, e.g. atenolol,20 it was obvious that parameters kPC-AOB and TPC-AOB
c  for acyclovir 323 
were lower than those values for atenolol (Table 1), indicating a stronger degradation ability 324 
of the AOB culture studied on atenolol than acyclovir. Considering the molecular differences 325 
between these two pharmaceuticals, this may imply an affinity property of AOB for different 326 
compounds probably due to a preferential substrate selection to AMO active sites.31 The 327 
parameter kPC-HET for acyclovir was 0.00035 ± 0.00002 m
3 g COD-1 h-1, which was in the 328 
same order of magnitude of the value estimated in this study (0.000180 ± 0.000017 m3 g 329 
COD-1 h-1) for atenolol. The conversion efficiencies from acyclovir to carboxy-acyclovir 330 
were 83.9%, 43.0% and 29.9% in Experiments 1, 2 and 3, respectively (see Figure 3). These 331 
results indicated the importance of metabolism of acyclovir by HET. Oxidation of acyclovir 332 
to carboxy-acyclovir might be dominated by unspecific monoxygenase from HET,32 which 333 
needs to be confirmed in the further work.  334 
 335 
Discussion 336 
In this work, a comprehensive mathematical model is developed to describe the 337 
biotransformation of pharmaceuticals and the formation of their products by enriched 338 
nitrifying cultures. In the proposed model, processes 1 and 2 (Table S2 in SI) depict the 339 
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AOB-induced cometabolic and metabolic biotransformation of pharmaceuticals, while 340 
processes 5 and 6 (Table S2 in SI) describe the HET-induced cometabolic and metabolic 341 
biotransformation of pharmaceuticals, respectively. Sensitivity analysis indicated that four 342 
key parameters kPC-HET, kPC-AOB, TPC-AOB
c and µ
max, AOB
 were critical to the model output and 343 
therefore estimated through model calibration. The validity of this biotransformation model is 344 
confirmed by independent atenolol biodegradation data and further evaluated by acyclovir 345 
biotransformation experiments. Compared to the previous studies where atenolol 346 
biodegradation was investigated through experiments and modeling approaches,20,21 the 347 
proposed model in this work considers the formation of biotransformation products and 348 
describes biotransformation of different pharmaceuticals under different metabolic conditions. 349 
This microbial processes-linked biotransformation model could enhance our ability to predict 350 
the fate of pharmaceuticals and their transformation products during wastewater treatment 351 
processes.  352 
Since we estimated four model parameters for fitting the experimental data, parameter 353 
uniqueness is important, since it is possible that different parameter combinations can give 354 
similar simulation accuracy.  In our work, we applied a least-squared analysis and evaluated 355 
standard errors and 95% confidence intervals of individual parameter estimates. The 356 
parameter confidence intervals showed a well-defined range in which the optimum values of 357 
parameters reside (Table 1), which indicates good uniqueness of these parameters. In addition 358 
to the analysis of the confidence intervals, two other aspects of our experimental design 359 
support the uniqueness of the parameter values. First, we used five different experimental 360 
parameters (ammonium, nitrite, DO, parent compound, and biotransformation product), 361 
which reflect different aspects of the kinetics of the two-step nitrification and pharmaceutical 362 
biotransformation by enriched nitrifying culture. Second, we carried out independent 363 
experiments to validate the estimated parameters. In particular, the good correspondence for 364 
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independent experimental data supports the validity of the new model and the uniqueness of 365 
the parameters for pharmaceutical biotransformation. 366 
The modeling results in this work suggested the cometabolism induced by AOB could 367 
play an important role in the pharmaceutical removal in the studied ratio ranges of 368 
pharmaceuticals to ammonia for cometabolism. Indeed a positive linear relationship was 369 
observed between ammonia oxidation rate and pharmaceutical degradation rates in terms of 370 
atenolol and acyclovir based on the validated model (Figure 4A). The atenolol degradation 371 
rate increased from 0.012 to 0.16 µg g VSS-1 h-1 while the nitrification rate increased from 372 
2.84 to 59.15 mg NH4
+-N g VSS-1 h-1. With respect to acyclovir, the degradation rate changed 373 
from 0.014 to 0.10 µg g VSS-1 h-1 whereas the ammonia oxidation rate showed an increase 374 
from 2.37 to 36.63 mg NH4
+-N g VSS-1 h-1. Such a positive correlation was also reported in 375 
previous literature under certain conditions,7,22,25 supporting the notion that majority of 376 
atenolol and acyclovir could be cometabolically degraded in the enriched nitrifying cultures. 377 
A further assessment on the wide application of the relationship was carried out by 378 
simulating the concentration profiles of pharmaceuticals after 240 h. The molar ratios of 379 
atenolol to ammonia from 8.42×10-7 to 1.91 ×10-5 calculated based on their concentrations 380 
was observed to be still within the range for a linearly positive relationship regarding the 381 
cometabolic biodegradation of atenolol by the enriched nitrifying cultures used in this work, 382 
and the relationship maintained at a same slope (Black solid squares in Figure 4A 383 
demonstrated the predicted atenolol degradation rate after 240 h). However, a different slope 384 
was found for the relationship between ammonia oxidation rate and the acyclovir degradation 385 
rate after 240 h predicted using the developed model (Figure 4B). If the ammonia oxidation 386 
rate was higher than the critical value (2.3 mg NH4
+-N g VSS-1 h-1 in this study), the lower 387 
slope might indicate a slower increasing trend in acyclovir degradation rate with an 388 
increasing ammonia oxidation rate (Figure 4A). Compared with the situation at the lower 389 
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ammonia oxidation rate, a higher increasing trend in acyclovir degradation rate would arise at 390 
higher slope (Figure 4B). The observation that pharmaceutical would not be degraded until 391 
the ammonia was depleted33 revealed a higher pharmaceutical degradation rate at lower 392 
ammonia oxidation rate, which supported the findings in this study. Regardless of the 393 
different slopes for the relationship, the molar ratios of acyclovir to ammonia ranging from 394 
1.62×10-11 to 2.26×10-5 was obtained to be a valid application range for the cometabolic 395 
biodegradation of acyclovir by the enriched nitrifying cultures used in this work. 396 
The proposed model framework was expected to be a useful tool to predict the 397 
biotransformation of pharmaceuticals and the formation of transformation products under 398 
varying conditions, therefore providing the guidance in designing, upgrading and optimizing 399 
of the relevant biological wastewater treatment processes. The influence of DO on 400 
pharmaceutical biotransformation was investigated by performing model simulations in the 401 
enriched nitrifying systems. The pharmaceutical removal efficiencies at 240 h at different DO 402 
concentrations ranging from 0 to 4 mg L-1 with ammonium concentration of 50 mg-N L-1 are 403 
shown in Figure 5. Overall DO concentration had a positive effect on pharmaceutical 404 
removal efficiencies. The concentrations of atenolol and acyclovir decreased rapidly with a 405 
prompt increase of atenolol acid and carboxy-acyclovir as DO increased to 1 mg L-1. With 406 
DO further increased to 4 mg L-1, a gradual decrease of pharmaceutical concentrations was 407 
observed accompanied with a slight increase of their biotransformation products. The 408 
degradation efficiencies for atenolol at DO concentrations of 0, 1 and 4 mg L-1 were 44.3%, 409 
83.2% and 94.0%, respectively. With regard to acyclovir, its degradation efficiencies were 410 
observed to be 36.2%, 81.2% and 87.3%, respectively at DO of 0, 1 and 4 mg L-1. The 411 
simulation results revealed that the DO concentration would play an important role in 412 
pharmaceutical biotransformation. This was contrary to the previous report that DO in the 413 
WWTP had no influence on oxidative biotransformation of selected micropollutants.34 The 414 
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possible reason could be that the experiments conducted in this study were nitrifying culture 415 
based instead of the regular activated sludge in WWTP, suggesting that DO might regulate 416 
the pharmaceutical biotransformation cometabolically. It should be noted that the simulation 417 
results are to provide insight into the potential impact of DO on pharmaceutical 418 
biotransformation by enriched nitrifying culture rather than to accurately predict the reality, 419 
which remain to be verified in future work. 420 
The growth substrate might also have an impact on the pharmaceutical biotransformation. 421 
Different ammonium concentrations ranging from 0 to 100 mg L-1 were applied in the model 422 
simulations at different DO concentrations as shown in Figure 6. It was obvious that the 423 
degradation efficiencies of studied pharmaceuticals and the formation rates of their 424 
transformation products would increase dramatically when ammonium concentrations 425 
increase from 0 to 20 mg-N L-1, especially in case of atenolol suggesting the importance of 426 
cometabolism on its biotransformation. However, there was no significant enhancement with 427 
the increase of ammonium concentrations from 20 to 250 mg-N L-1 (data of 100-250 mg-N L-428 
1 were not shown). This was contrary to the previous report where the removal efficiencies of 429 
the selected pharmaceuticals were enhanced at higher initial ammonium concentrations.35 430 
This could be probably due to the substrate competition between growth substrate 431 
(ammonium) and cometabolic substrates (e.g. atenolol or acyclovir). Pharmaceutical levels 432 
applied in this study were several orders of magnitude lower than the investigated ammonium 433 
concentrations, leading to a competition for AMO active sites and therefore potential 434 
decreasing degradation rates at higher ammonium concentrations.31,33  435 
In summary, a comprehensive model that considers all microbial processes contributing 436 
to pharmaceutical biotransformation as well as the formation of biotransformation products 437 
by the enriched nitrifying cultures is developed in this work. The proposed model was 438 
successfully calibrated and validated using the biotransformation experiments of atenolol and 439 
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acyclovir under different metabolic conditions. The linear positive correlation between 440 
ammonia oxidation rate and pharmaceutical degradation rate confirmed the major role of 441 
cometabolism induced by AOB in the pharmaceutical removal. DO was revealed to be 442 
capable of regulating the pharmaceutical biotransformation cometabolically and the substrate 443 
competition between ammonium and pharmaceuticals existed at high ammonium 444 
concentrations. More verification should be conducted using other pharmaceuticals’ 445 
biotransformation data for this developed model to facilitate its application as a useful tool in 446 
prediction of pharmaceutical fate, especially in the real municipal wastewater systems, where 447 
other processes (e.g., the competition between different parent compounds on the enzyme 448 
active sites) need to be considered in future work. 449 
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Table and Figure Legends 566 
 567 
Table 1. Estimated parameter values for the biotransformation model in this study 568 
 569 
Figure 1. Model calibration with experimental data from atenolol biodegradation: (A) 570 
Experiment 1, with addition of allylthiourea (ATU); (B) Experiment 2, in the absence of 571 
ammonium; and (C) Experiment 3, in the presence of ammonium (50 mg NH4
+-N L-1). 572 
 573 
Figure 2. Model validation results of atenolol biotransformation by the enriched nitrifying 574 
culture in the presence of ammonium of 25 mg-N L-1 (Experiment 4). 575 
 576 
Figure 3. Model evaluation with experimental data from acyclovir biodegradation: (A) 577 
Experiment 1, with addition of allylthiourea (ATU), (B) Experiment 2, in the absence of 578 
ammonium and (C) Experiment 3, in the presence of ammonium (50 mg NH4
+-N L-1). 579 
 580 
Figure 4. (A) The relationship between ammonia oxidizing rate and the pharmaceutical 581 
degradation rates in terms of atenolol and acyclovir (black solid squares indicate the atenolol 582 
degradation rates after 240 h); and (B) The relationship between ammonia oxidizing rate and 583 
the acyclovir degradation rate after 240 h at a different linear fit slope. 584 
 585 
Figure 5. Predicted final concentrations of (A) atenolol and atenolol acid and (B) acyclovir 586 
and carboxy-acyclovir at time of 240 h at different concentrations of dissolved oxygen (DO) 587 
in the enriched nitrifying culture system. 588 
 589 
Figure 6. Predicted concentrations of pharmaceuticals and their transformation products at 590 
time of 240 h at initial concentrations of 15 µg L-1 with different ammonium concentrations 591 
ranging from 0 to 100 mg-N L-1 at different DO levels.  592 
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Table 1. Estimated parameter values for the biotransformation model in this study 593 
Parameters Definition Unit 
Estimated 
atenolol acyclovir 
kPC-HET 
Heterotrophs (HET) transformation 
coefficient 
m3 g COD-1 h-1 
0.000180 
± 
0.000017 
0.00035 ± 
0.00002 
kPC-AOB 
Ammonia oxidizing bacteria (AOB) 
transformation coefficient 
m3 g COD-1 h-1 
0.000140 
± 
0.000012 
0.00005 ± 
0.00003 
TPC-AOB
c
 
Parent compound biotransformation 
coefficient rate linked to AOB 
growth (cometabolism) 
m3 g COD-1 
0.012 ± 
0.000036 
0.00093 ± 
0.00049 
µ
max, AOB
 
Maximum specific growth rate of 
AOB 
h-1 0.012 ± 0.0023 
  594 
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 595 
Figure 1. Model calibration with experimental data from atenolol biodegradation: (A) 596 
Experiment 1, with addition of allylthiourea (ATU); (B) Experiment 2, in the absence of 597 
ammonium; and (C) Experiment 3, in the presence of ammonium (50 mg NH4
+-N L-1). 598 
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 599 
 600 
Figure 2. Model validation results of atenolol biotransformation by the enriched nitrifying 601 
culture in the presence of ammonium of 25 mg-N L-1 (Experiment 4).  602 
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 604 
 605 
Figure 3. Model evaluation with experimental data from acyclovir biodegradation: (A) 606 
Experiment 1, with addition of allylthiourea (ATU), (B) Experiment 2, in the absence of 607 
ammonium and (C) Experiment 3, in the presence of ammonium (50 mg NH4
+-N L-1). 608 
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 609 
Figure 4. (A) The relationship between ammonia oxidizing rate and the pharmaceutical 610 
degradation rates in terms of atenolol and acyclovir (black solid squares indicate the atenolol 611 
degradation rates after 240 h); and (B) The relationship between ammonia oxidizing rate and 612 
the acyclovir degradation rate after 240 h at a different linear fit slope.  613 
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 614 
Figure 5. Predicted final concentrations of (A) atenolol and atenolol acid and (B) acyclovir 615 
and carboxy-acyclovir at time of 240 h at different concentrations of dissolved oxygen (DO) 616 
in the enriched nitrifying culture system.  617 
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 618 
Figure 6. Predicted concentrations of pharmaceuticals and their transformation products at 619 
time of 240 h at initial concentrations of 15 µg L-1 with different ammonium concentrations 620 
ranging from 0 to 100 mg-N L-1 at different DO levels. 621 
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